AtriCure provides treatments for atrial fibrillation (Afib), left atrial appendage management and post-operative pain. Co.'s ablation and left atrial appendage management products are used by physicians during both open-heart and minimally invasive procedures. Co.'s Isolator® Synergy Ablation System is approved by U.S. Food and Drug Administration (FDA) for the treatment of persistent and long-standing persistent Afib concomitant to other open-heart surgical procedures. The EPi-Sense® system is approved by FDA to treat patients with long-standing persistent Afib. All of Co.'s other ablation devices are cleared for sale in U.S., including its other radio frequency and cryoablation products. The ATRC stock yearly return is shown above.
The yearly return on the ATRC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ATRC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|